Evgeny A. Zemskov, Ph.D.

Associate Professor

Cellular Biology & Pharmacology

Office: CTS 305

Phone: 772-345-4692

Email: ezemskov@fiu.edu

Evgeny A. Zemskov, Ph.D., is an associate professor at the Center for Translational Science and the Department of Cellular Biology and Pharmacology. Zemskov joined HWCOM in 2021. He is involved in biomedical translational research related to lung pathologies.


Post-doctoral training, UMD School of Medicine Center for Vascular and Inflammatory Diseases, Baltimore, MD
Post-doctoral training, RIKEN Institute, Tokyo, Japan
Ph.D., Biochemistry, Russian Academy of Sciences, Moscow, Russia
M.S., Biochemistry, Moscow State University, Moscow, Russia

Research interest

Zemskov’s areas of expertise are Biochemistry, Cellular and Molecular Biology. His research interests include investigating the molecular mechanisms of vascular hyperpermeability in acute lung injury (ALI) and ventilator-induced lung injury (VILI), as well as approaches to protect the barrier function of pulmonary endothelium and endothelial integrity. Zemskov has co-authored more than 50 research papers and review articles. Results of his research have been presented at numerous national and international scientific conferences.


Project: PKG Signaling and Sepsis Induced ALI
Faculty Names: Stephen M Black, Evgeny A Zemskov
Role: Multiple Principal Investigators
Sponsor: National Institutes of Health
Period: July 2018 – June 2022
Total Funding: $1,801,948
Grant Type: Extramural Grant

Selected publications

  1. Zemskov E. A., Wu X., Aggarwal S., Yegambaram M., Gross C., Lu Q., Wang H., Tang H., Wang T., and Black S. M. (2021) Protein kinase G-1α modulates cyclic nucleotide crosstalk via phosphodiesterase 3A: implications for acute lung injury. Journal of Biological Chemistry. 297:100946.
  2. Lu Q., Zemskov E. A., Sun X., Wang H., Yegambaram M., Wu X., Garcia A., Song S., Tang H., Kangath A., Yuan J. X.-J., Wang T., Fineman J. R., and Black S. M. (2021) Activation of the mechanosensitive Ca2+ channel TRPV4 induces endothelial barrier permeability via the disruption of mitochondrial bioenergetics. Redox Biology. 38:101785.
  3. Zemskov E. A., Lu Q., Ornatowski W., Klinger C. N., Desai A. A., Maltepe E., Yuan J. X., Wang T., Fineman J. R., and Black S. M. (2019) Biomechanical forces and oxidative stress: implications for pulmonary vascular disease. Antioxidants and Redox Signaling, 31: 819-842.
  4. Rafikova O., Williams E. R., McBride M. L., Zemskova M., Srivastava A., Nair V., Desai A. A., Langlais P. R., Zemskov E., Simon M., Mandarino L. J., and Rafikov R. (2018) Hemolysis-induced lung vascular leakage contributes to the development of pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology. 59(3):334-345.
  5. Gonzales J. N., Kim K. M., Zemskova M. A., Rafikov R., Heeke B., Varn M. N., Black S., Kennedy T. P., Verin A. D., and Zemskov E. A. (2014) Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent manner. Vascular Pharmacology, 62, 63-71.
  6. Lucas R., Sridhar S., Rick F. G., Gorshkov B., Umapathy N. S., Yang G., Oseghale A., Verin A. D., Chakraborty T., Matthay M. A., Zemskov E. A., White R., Block N. L., and Schally A. V. (2012) Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema. Proceedings of the National Academy of Sciences of the USA, 109, 2084-2089.